134 related articles for article (PubMed ID: 2291265)
1. [What importance do tumor markers have in life insurance medicine?].
Binsack T; Kraus HK
Versicherungsmedizin; 1990 Dec; 42(6):157-62. PubMed ID: 2291265
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic sensitivity, diagnostic specificity and predictive value of the determination of tumour markers.
Wagener C
J Clin Chem Clin Biochem; 1984 Dec; 22(12):969-79. PubMed ID: 6527105
[TBL] [Abstract][Full Text] [Related]
3. A review of the role of established tumour markers.
Beastall GH; Cook B; Rustin GJ; Jennings J
Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():5-18. PubMed ID: 2024935
[TBL] [Abstract][Full Text] [Related]
4. [Biological markers of cancer. Critical study].
Bellet D; Bidart JM
Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
[TBL] [Abstract][Full Text] [Related]
5. Follow-up care of cancer survivors.
Galassi A
Lippincotts Prim Care Pract; 2000; 4(4):359-70; quiz 371-3. PubMed ID: 11261113
[No Abstract] [Full Text] [Related]
6. [Immunodiagnosis of cancer: requirements and results (author's transl)].
Pasternak G; von Broen B
Arch Geschwulstforsch; 1980; 50(3):230-7. PubMed ID: 6159868
[TBL] [Abstract][Full Text] [Related]
7. Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000.
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM;
Br J Cancer; 2003 Aug; 89 Suppl 1(Suppl 1):S32-4. PubMed ID: 12915901
[No Abstract] [Full Text] [Related]
8. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of novel tumour markers.
Rhodes JM
Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801
[TBL] [Abstract][Full Text] [Related]
10. [Immunologic tumor diagnosis].
Schmolke B
Z Lymphol; 1990 Dec; 14(2):58-61. PubMed ID: 2087871
[TBL] [Abstract][Full Text] [Related]
11. Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors.
Huguet J
Actas Urol Esp; 2013 Jun; 37(6):376-82. PubMed ID: 23611464
[TBL] [Abstract][Full Text] [Related]
12. [Application of tumour markers in clinical practice].
Keuren JF; Thomas CM; Bonfrèr JM; Sweep CG; Boonstra JG
Ned Tijdschr Geneeskd; 2009; 153():A617. PubMed ID: 19857306
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
Voorzanger-Rousselot N; Garnero P
Cancer Treat Rev; 2007 May; 33(3):230-83. PubMed ID: 17433551
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.
Vihinen P; Kähäri VM
Int J Cancer; 2002 May; 99(2):157-66. PubMed ID: 11979428
[TBL] [Abstract][Full Text] [Related]
15. New placental and pregnancy proteins as possible markers in oncology.
Bohn H
Klin Wochenschr; 1980 May; 58(10):489-92. PubMed ID: 6993772
[TBL] [Abstract][Full Text] [Related]
16. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
17. Predicting recurrence and metastasis of primary esophageal cancer with or without lymph node metastasis.
Tajima T; Mukai M; Sato S; Ninomiya H; Wakui K; Komatsu N; Tsuchiya K; Nakasaki H; Makuuchi H
Oncol Rep; 2006 Apr; 15(4):809-14. PubMed ID: 16525663
[TBL] [Abstract][Full Text] [Related]
18. [Tumor markers].
Fiebiger W; Wiltschke C
Acta Med Austriaca; 2001; 28(2):33-7. PubMed ID: 11382139
[TBL] [Abstract][Full Text] [Related]
19. [Oncofetal proteins - their character and clinical significance as tumour-markers (author's transl)].
Ziegenbein R
Zentralbl Chir; 1980; 105(23):1537-45. PubMed ID: 6163265
[TBL] [Abstract][Full Text] [Related]
20. Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.
Baker SG; Kramer BS
J Clin Oncol; 2015 Aug; 33(23):2578-80. PubMed ID: 26124476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
